Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

NCT07336797 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Metabolic Syndrome
Obesity & Overweight
HIV (Human Immunodeficiency Virus)

Interventions

DRUG: Empagliflozin (oral)
DRUG: Placebo

Sponsor

Abdelrahman Mahmoud